GSK plc (BVMF:G1SK34)
| Market Cap | 572.85B +15.0% |
| Revenue (ttm) | 230.67B +4.3% |
| Net Income | 29.92B -20.8% |
| EPS | 3.27 -19.7% |
| Shares Out | n/a |
| PE Ratio | 17.49 |
| Forward PE | 10.01 |
| Dividend | 1.72 (3.01%) |
| Ex-Dividend Date | Nov 12, 2026 |
| Volume | 3 |
| Open | 56.94 |
| Previous Close | 58.62 |
| Day's Range | 56.94 - 57.18 |
| 52-Week Range | 46.15 - 63.24 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK Wins FDA Approval For Nelkarmi In Previously Treated ALK-Positive Lung Cancer
(RTTNews) - GSK plc (GSK) announced that the U.S. FDA has granted accelerated approval to Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (...
GSK Gets FDA Approval for New Lung-Cancer Drug
GSK can now launch a new medicine in the U.S. for lung cancer, a move that bolsters its efforts to build a franchise in a disease that is the leading cause of cancer death.
GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap
GSK NYSE: GSK Chief Financial Officer Julie Brown said oncology products could help close the gap between analysts' sales expectations and the company's target of more than £40 billion in annual sales...
GSK confirms FDA accelerated approval of Nelkarmi for non-small cell lung cancer
GSK (GSK) announced the U.S. Food and Drug Administration has granted accelerated approval to Nelkarmi for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase-positi...
FDA grants accelerated approval to GSK's lung cancer drug
The US FDA on Tuesday granted accelerated approval to GSK's therapy for a rare form of advanced lung cancer in patients whose disease has worsened on existing drugs, marking another regulatory win f...
GSK plc Transcript: J.P. Morgan UK Leaders Conference
Accelerated R&D investment is supported by a GBP 1.9bn savings plan and 22 Phase III starts by year-end 2026. Launches, oncology pipeline catalysts and long-acting HIV treatments underpin the >GBP 40bn 2031 sales ambition.
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President o...
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology busi...
GSK plc Transcript: Jefferies Global Healthcare Conference
Long-acting HIV programs are advancing toward four-month dosing, with six-month regimens targeted for the early 2030s. More than 20 phase III starts, continued BD and a £1.9bn cost program support growth through patent expiries and a larger oncology ambition.
GSK: 3 Key Takeaways for Long-Term Investors
Cost discipline is offsetting R&D investment without squeezing margins, the financial foundation for sustained portfolio transformation.
GSK price target lowered to 2,050 GBp from 2,100 GBp at Citi
Citi lowered the firm’s price target on GSK (GSK) to 2,050 GBp from 2,100 GBp and keeps a Neutral rating on the shares.
GSK price target lowered to 2,050 GBp from 2,100 GBp at Citi
Citi analyst Graham Parry lowered the firm’s price target on GSK (GSK) to 2,050 GBp from 2,100 GBp and keeps a Neutral rating on the shares.
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, ...
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus ...
GSK plc Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
R&D is centered on human causal evidence, responder biomarkers and predictive combinations. Next-year priorities include IL-33 airway milestones, data from six pivotal TSLP studies and planned phase III programs in food allergy and spontaneous urticaria.
GSK plc Announces Provisional Dividend Dates for 2027
GSK plc, whose filing was received under BlackRock ETF Trust II - iShares Flexible Income Active ETF, has announced its provisional dividend dates for 2027. The company noted that these dates are indi...
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
GSK showcases progress in liver portfolio at AASLD 2026
GSK (GSK) will present new data from its advancing liver portfolio at the American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2026, taking place in Denver,…
GSK’s ViiV Healthcare commits $100M to build local HIV care networks in US
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced a $100M, three-year commitment through its U.S. Positive Action program, to pr...
Ex-GSK boss Emma Walmsley hired to take controls of US tech giant HP
Former GSK boss Emma Walmsley has been hired to take the controls of US-based computer maker HP as it grapples with AI-driven turbulence.
Who is HP’s new CEO Emma Walmsley?
HP Inc. named former GSK chief and Microsoft board member Emma Walmsley as CEO to steer the PC maker through a memory-chip shortage.
Who is HP's new CEO Emma Walmsley?
HP Inc on Wednesday named former GSK chief and Microsoft board member Emma Walmsley as CEO to steer the PC maker through a memory-chip shortage that has driven up prices and triggered a steep industry...
HP Inc. appoints Emma Walmsley as CEO
HP Inc. (HPQ) announced that its board of directors has unanimously appointed Emma Walmsley as CEO, effective January 4, 2027. Walmsley most recently served as CEO of GSK (GSK) and…
HP names former GSK chief Emma Walmsley as CEO
HP Inc on Wednesday named former GSK chief and Microsoft board member Emma Walmsley as CEO to steer the PC maker through a memory-chip shortage that has driven up prices and triggered a steep industry...
Alamar Biosciences partners with GSK on 60,000-sample proteomic study
Alamar Biosciences (ALMR) announced a strategic scientific collaboration with GSK (GSK) that will use Alamar’s NULISA platform in a large-scale study examining how circulating protein signatures relat...